https://www.selleckchem.com/products/caffeic-acid-phenethyl-ester.html Bempedoic acid is a new lipid-lowering drug that inhibits cholesterol biosynthesis in liver cells selectively. Results from phase 2 and phase 3 studies showed a complementary effect on LDL-cholesterol lowering when combining bempedoic acid and ezetimibe without increasing side effects. Moreover, bempedoic acid seems to represent a good treatment option for the management of hypercholesterolemia, especially in patients at increased risk of cardiovascular events, such as patients with impaired glucose metabolism, elderly patients, patients with prior acute coronary syndrome, and patients with familial hypercholesterolemia. Based on the scientific evidence, this paper provides practical recommendations on the management of hypercholesterolemia with bempedoic acid.The efficacy and safety of bempedoic acid, including the occurrence of muscle-related adverse events, have been addressed by phase 2 and phase 3 clinical trials. Phase 3 clinical trials demonstrated that in patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolemia who were treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, bempedoic acid treatment was associated with a significant reduction in low-density lipoprotein cholesterol in different groups of patients with a favorable safety profile. An ongoing phase 3 study is currently evaluating the effect of longer-term (median duration of 3-4 years) treatment with bempedoic acid on the incidence of cardiovascular events.Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase. Bempedoic acid is a prodrug rapidly converted in the liver to a coenzyme A derivate, ETC-1200-CoA, by an endogenous liver very long-chain acyl-CoA synthetase-1 (ACSVL1). Since ACSVL1 is not present